Invitae Acquires YouScript and Genelex

Genezen Acquires uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

July 1, 2024

Biotechnology

Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.

Novacyt Acquires Yourgene Health plc

September 8, 2023

Medical Devices

Novacyt, through its wholly-owned subsidiary Novacyt UK Holdings Limited, has completed the acquisition of Yourgene Health plc by way of a court-sanctioned scheme of arrangement. The deal brings together Novacyt's diagnostics capabilities with Yourgene's genomic technologies and services to create a larger, diversified international molecular diagnostics business headquartered in Manchester, UK.

Inscripta Acquires Infinome Biosciences and Sestina Bio

January 18, 2023

Biotechnology

Inscripta, a genome engineering company based in Pleasanton, California, has acquired synthetic biology firms Infinome Biosciences and Sestina Bio to accelerate its capabilities in sustainable biomanufacturing. The acquisitions integrate Infinome's GenoScaler strain-engineering platform and Sestina's data-driven scale-up strain design to advance Inscripta's commercialization of bio-manufactured products for industrial and consumer markets.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform

June 22, 2020

Healthcare Services

Invitae has entered into a definitive agreement to acquire ArcherDX in a cash-and-stock transaction valued at approximately $1.4 billion, combining Invitae's diagnostic and hereditary testing capabilities with ArcherDX's somatic genomics, liquid biopsy and bioinformatics platform. The deal is intended to integrate germline and somatic testing, expand precision oncology offerings, and accelerate adoption of comprehensive cancer genetics across clinical and biopharma customers worldwide.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.